{"id":494847,"date":"2021-05-18T07:33:28","date_gmt":"2021-05-18T11:33:28","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-to-conduct-shareholder-update-conference-call-tuesday-may-25-2021-at-430-pm-et\/"},"modified":"2021-05-18T07:33:28","modified_gmt":"2021-05-18T11:33:28","slug":"brooklyn-immunotherapeutics-to-conduct-shareholder-update-conference-call-tuesday-may-25-2021-at-430-pm-et","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-to-conduct-shareholder-update-conference-call-tuesday-may-25-2021-at-430-pm-et\/","title":{"rendered":"Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call Tuesday May 25, 2021 at 4:30 PM ET"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call Tuesday May 25, 2021 at 4:30 PM ET<\/b><\/p>\n<p>BROOKLYN, N.Y.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fbrooklynitx.com%2F&amp;esheet=52431223&amp;newsitemid=20210518005370&amp;lan=en-US&amp;anchor=Brooklyn+ImmunoTherapeutics&amp;index=1&amp;md5=98655823020abeb795d74dc566f84f53\">Brooklyn ImmunoTherapeutics<\/a>, Inc. (NYSE American: BTX) (&#8220;Brooklyn&#8221; or the \u201cCompany\u201d), a biopharmaceutical company currently focused on exploring the role that cytokine and gene editing\/cell therapy can have in treating patients with cancer, blood disorders and monogenic diseases, today announced that management will host a conference call on Tuesday, May 25, 2021 at 4:30 p.m. Eastern Time (ET).\n<\/p>\n<p>\nParticipants are asked to pre-register for the call through the following link: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.directeventreg.com%2Fregistration%2Fevent%2F6819283&amp;esheet=52431223&amp;newsitemid=20210518005370&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.directeventreg.com%2Fregistration%2Fevent%2F6819283&amp;index=2&amp;md5=b2384825ca767b8fca4747cf78fc7615\">http:\/\/www.directeventreg.com\/registration\/event\/6819283<\/a>. Please note that registered participants will receive their dial in number upon registration and will dial directly into the call.\n<\/p>\n<p>\nThe conference call will also be available through a live webcast found <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fevent.on24.com%2Fwcc%2Fr%2F3141506%2F5C0BB109FCF080913ED0C5B56F71B62E&amp;esheet=52431223&amp;newsitemid=20210518005370&amp;lan=en-US&amp;anchor=here.&amp;index=3&amp;md5=b63f2303c2e847cad3bf51b23d37dfdf\">here.<\/a><\/p>\n<p>\nThe Company invites participants to pre-submit questions to <a rel=\"nofollow\" href=\"mailto:investors@brooklyntx.com\">investors@brooklyntx.com<\/a> until 5:00 p.m. Eastern Time (ET) on May 20, 2021 (live questions will not be accepted during the call). Please use the subject line, \u201cBTX Call Questions\u201d for this correspondence. The Company will do its best to address all pre-submitted questions at the conclusion of prepared remarks.\n<\/p>\n<p><b>About Brooklyn ImmunoTherapeutics<\/b><\/p>\n<p>\nBrooklyn is focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. The company is also expoloring opportunities to advance oncology, blood disorders, and monogenic disease therapies using leading edge gene editing\/cell therapy technology through the newly acquired license from Factor Bioscience Limited and Novellus Therapeutics Limited.\n<\/p>\n<p>\nBrooklyn\u2019s most advanced program is studying the safety and efficacy of IRX-2 in patients with head and neck cancer. In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. Additional studies are either underway or planned in other solid tumor cancer indications.\n<\/p>\n<p>\nFor more information about Brooklyn and its clinical programs, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.brooklynitx.com%2F&amp;esheet=52431223&amp;newsitemid=20210518005370&amp;lan=en-US&amp;anchor=www.BrooklynITx.com&amp;index=4&amp;md5=14d8c7f5bc94ee5bbdbdc9adf7b732c6\">www.BrooklynITx.com<\/a>.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210518005370r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210518005370\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210518005370\/en\/<\/a><\/span><\/p>\n<p><b>Investor Relations Contact:<br \/>\n<br \/><\/b>CORE IR<br \/>\n<br \/>516-222-2560<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:investors@brooklynitx.com\">investors@brooklynitx.com<\/a><\/p>\n<p><b>Media Contact:<br \/>\n<\/b><br \/>MacDougall<br \/>\n<br \/>Nicholas Chang<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:nchang@macbiocom.com\">nchang@macbiocom.com<br \/>\n<\/a><br \/>781-235-3060\n<\/p>\n<p><b>KEYWORDS:<\/b> New York United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Health<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210518005370\/en\/689078\/3\/Brooklyn-ITX_Final_Logo_RGB_300dpi.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call Tuesday May 25, 2021 at 4:30 PM ET BROOKLYN, N.Y.&#8211;(BUSINESS WIRE)&#8211;Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (&#8220;Brooklyn&#8221; or the \u201cCompany\u201d), a biopharmaceutical company currently focused on exploring the role that cytokine and gene editing\/cell therapy can have in treating patients with cancer, blood disorders and monogenic diseases, today announced that management will host a conference call on Tuesday, May 25, 2021 at 4:30 p.m. Eastern Time (ET). Participants are asked to pre-register for the call through the following link: http:\/\/www.directeventreg.com\/registration\/event\/6819283. Please note that registered participants will receive their dial in number upon registration and will dial directly into the call. The conference call will also be available through a live webcast found &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-to-conduct-shareholder-update-conference-call-tuesday-may-25-2021-at-430-pm-et\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call Tuesday May 25, 2021 at 4:30 PM ET&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-494847","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call Tuesday May 25, 2021 at 4:30 PM ET - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-to-conduct-shareholder-update-conference-call-tuesday-may-25-2021-at-430-pm-et\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call Tuesday May 25, 2021 at 4:30 PM ET - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call Tuesday May 25, 2021 at 4:30 PM ET BROOKLYN, N.Y.&#8211;(BUSINESS WIRE)&#8211;Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (&#8220;Brooklyn&#8221; or the \u201cCompany\u201d), a biopharmaceutical company currently focused on exploring the role that cytokine and gene editing\/cell therapy can have in treating patients with cancer, blood disorders and monogenic diseases, today announced that management will host a conference call on Tuesday, May 25, 2021 at 4:30 p.m. Eastern Time (ET). Participants are asked to pre-register for the call through the following link: http:\/\/www.directeventreg.com\/registration\/event\/6819283. Please note that registered participants will receive their dial in number upon registration and will dial directly into the call. The conference call will also be available through a live webcast found &hellip; Continue reading &quot;Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call Tuesday May 25, 2021 at 4:30 PM ET&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-to-conduct-shareholder-update-conference-call-tuesday-may-25-2021-at-430-pm-et\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-18T11:33:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210518005370r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-to-conduct-shareholder-update-conference-call-tuesday-may-25-2021-at-430-pm-et\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-to-conduct-shareholder-update-conference-call-tuesday-may-25-2021-at-430-pm-et\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call Tuesday May 25, 2021 at 4:30 PM ET\",\"datePublished\":\"2021-05-18T11:33:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-to-conduct-shareholder-update-conference-call-tuesday-may-25-2021-at-430-pm-et\\\/\"},\"wordCount\":374,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-to-conduct-shareholder-update-conference-call-tuesday-may-25-2021-at-430-pm-et\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210518005370r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-to-conduct-shareholder-update-conference-call-tuesday-may-25-2021-at-430-pm-et\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-to-conduct-shareholder-update-conference-call-tuesday-may-25-2021-at-430-pm-et\\\/\",\"name\":\"Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call Tuesday May 25, 2021 at 4:30 PM ET - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-to-conduct-shareholder-update-conference-call-tuesday-may-25-2021-at-430-pm-et\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-to-conduct-shareholder-update-conference-call-tuesday-may-25-2021-at-430-pm-et\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210518005370r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-05-18T11:33:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-to-conduct-shareholder-update-conference-call-tuesday-may-25-2021-at-430-pm-et\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-to-conduct-shareholder-update-conference-call-tuesday-may-25-2021-at-430-pm-et\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-to-conduct-shareholder-update-conference-call-tuesday-may-25-2021-at-430-pm-et\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210518005370r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210518005370r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-to-conduct-shareholder-update-conference-call-tuesday-may-25-2021-at-430-pm-et\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call Tuesday May 25, 2021 at 4:30 PM ET\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call Tuesday May 25, 2021 at 4:30 PM ET - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-to-conduct-shareholder-update-conference-call-tuesday-may-25-2021-at-430-pm-et\/","og_locale":"en_US","og_type":"article","og_title":"Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call Tuesday May 25, 2021 at 4:30 PM ET - Market Newsdesk","og_description":"Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call Tuesday May 25, 2021 at 4:30 PM ET BROOKLYN, N.Y.&#8211;(BUSINESS WIRE)&#8211;Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (&#8220;Brooklyn&#8221; or the \u201cCompany\u201d), a biopharmaceutical company currently focused on exploring the role that cytokine and gene editing\/cell therapy can have in treating patients with cancer, blood disorders and monogenic diseases, today announced that management will host a conference call on Tuesday, May 25, 2021 at 4:30 p.m. Eastern Time (ET). Participants are asked to pre-register for the call through the following link: http:\/\/www.directeventreg.com\/registration\/event\/6819283. Please note that registered participants will receive their dial in number upon registration and will dial directly into the call. The conference call will also be available through a live webcast found &hellip; Continue reading \"Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call Tuesday May 25, 2021 at 4:30 PM ET\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-to-conduct-shareholder-update-conference-call-tuesday-may-25-2021-at-430-pm-et\/","og_site_name":"Market Newsdesk","article_published_time":"2021-05-18T11:33:28+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210518005370r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-to-conduct-shareholder-update-conference-call-tuesday-may-25-2021-at-430-pm-et\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-to-conduct-shareholder-update-conference-call-tuesday-may-25-2021-at-430-pm-et\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call Tuesday May 25, 2021 at 4:30 PM ET","datePublished":"2021-05-18T11:33:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-to-conduct-shareholder-update-conference-call-tuesday-may-25-2021-at-430-pm-et\/"},"wordCount":374,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-to-conduct-shareholder-update-conference-call-tuesday-may-25-2021-at-430-pm-et\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210518005370r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-to-conduct-shareholder-update-conference-call-tuesday-may-25-2021-at-430-pm-et\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-to-conduct-shareholder-update-conference-call-tuesday-may-25-2021-at-430-pm-et\/","name":"Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call Tuesday May 25, 2021 at 4:30 PM ET - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-to-conduct-shareholder-update-conference-call-tuesday-may-25-2021-at-430-pm-et\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-to-conduct-shareholder-update-conference-call-tuesday-may-25-2021-at-430-pm-et\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210518005370r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-05-18T11:33:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-to-conduct-shareholder-update-conference-call-tuesday-may-25-2021-at-430-pm-et\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-to-conduct-shareholder-update-conference-call-tuesday-may-25-2021-at-430-pm-et\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-to-conduct-shareholder-update-conference-call-tuesday-may-25-2021-at-430-pm-et\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210518005370r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210518005370r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-to-conduct-shareholder-update-conference-call-tuesday-may-25-2021-at-430-pm-et\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call Tuesday May 25, 2021 at 4:30 PM ET"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/494847","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=494847"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/494847\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=494847"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=494847"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=494847"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}